Biotech firm 22nd Century Group has reported revised terms for their divestiture of cannabinoid related interests.  Since Fastmarkets reported on this last week, 22nd Century Group was able to secure improved terms for the sale to Nevada-based Specialty Acquisition Corporation after consent by one of 22^nd Century Group’s senior lenders.

The updated terms include a cash payment of $1.1 million from Specialty Acquisition Corporation

…